144034-84-4

Basic information

• Product Name: DESMETHYL RIZATRIPTAN
• Synonyms: DESMETHYL RIZATRIPTAN;N10-Monodesmethyl Rizatriptan;N-Methyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine;N-MonodesMethyl Rizatriptan;Rizatriptan N-monodesmethyl
• CAS NO: 144034-84-4
• Molecular Formula: C14H17N5
• Molecular Weight: 255.32
• EINECS: 604-604-1
• Product Categories: Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Heterocycles
• Mol File: 144034-84-4.mol

Chemical Properties

• Boiling Point: 515.644°C at 760 mmHg
• Flash Point: 265.652°C
• Appearance: /
• Density: 1.269g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.673
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: DESMETHYL RIZATRIPTAN(CAS DataBase Reference)
• NIST Chemistry Reference: DESMETHYL RIZATRIPTAN(144034-84-4)
• EPA Substance Registry System: DESMETHYL RIZATRIPTAN(144034-84-4)

Safety Data

• Hazardous Substances Data: 144034-84-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DESMETHYL RIZATRIPTAN is used as an impurity reference substance for the quality control and analysis of Rizatriptan in the pharmaceutical industry. As a metabolite of Rizatriptan, it plays a role in understanding the pharmacokinetics and pharmacodynamics of the parent drug, which can be crucial for drug development and optimization.
Additionally, DESMETHYL RIZATRIPTAN may be used as a research compound to study the metabolic pathways and effects of Rizatriptan in the body. This can contribute to the development of new medications or improved formulations with better efficacy and safety profiles for the treatment of migraines and other related conditions.

InChI:InChI=1/C14H17N5/c1-15-5-4-12-7-17-14-3-2-11(6-13(12)14)8-19-10-16-9-18-19/h2-3,6-7,9-10,15,17H,4-5,8H2,1H3

Upstream product

• 1198110-33-6 ethyl [2-[5-[(1H-1,2,4-triazol-1-yl)methyl]-1H-indol-3-yl]ethyl]carbamate 
• 114094-45-0 methyl-aminobutyraldehyde diethyl acetal 
• 144035-22-3 4-(1,2,4-triazol-1-ylmethyl)phenylhydrazine 
• 74-89-5 methylamine 

Relevant articles and documents

Synthesis and characterization of potential impurities of the antimigraine drug, rizatriptan benzoate

Rizatriptan benzoate is a recently developed antimigraine drug used for the treatment of migraines and severe headaches. In the synthesis of rizatriptan benzoate in bulk,various impurities are formed. The present work details the development of a simple a

N-Desmethyltriptans: One pot efficient synthesis of N-methyl-2-5- [substituted- 1H- indole-3-yl]ethanamines

A straightforward and highly improved method to synthesize N-methyl-2-[5-[substituted-lH-indole-3-yl]ethanamines 4-6, which are the metabolites of tryptans 1-3, is reported. The significance of the process is its simplicity and efficiency in isolating the N- desmethyltriptans derivatives as a free base.

Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists

PCT No. PCT/GB97/01137 Sec. 371 Date Oct. 14, 1998 Sec. 102(e) Date Oct. 14, 1998 PCT Filed Apr. 24, 1997 PCT Pub. No. WO97/42189 PCT Pub. Date Nov. 13, 1997A class of compounds of formula (I) wherein Z, E, Q, T, U, V, W, M, R1, R7 and R8 are as defined herein; are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1D alpha receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1D alpha receptor subtype relative to the 5-HT1D beta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

Triazole containing indole derivatives

A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT 1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.